Acadia’s 50-day moving average is in the process of crossing above the stock’s 200-day moving average. This crossover forms a ...

Guggenheim has recently reduced ACADIA Pharmaceuticals Inc (ACAD) stock to Neutral rating, as announced on January 3, 2025, according to Finviz. Earlier, on October 10, 2024, Raymond James had resumed ...

Fintel reports that on January 3, 2025, Guggenheim downgraded their outlook for ACADIA Pharmaceuticals (NasdaqGS:ACAD) from ...

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) was downgraded by Guggenheim from a “buy” rating to a “neutral” rating ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $18.66, but opened at $18.25. ACADIA ...

We recently published a list of 10 Firms End 2024 Stronger With Impressive Gains. In this article, we are going to take a ...

In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against other firms end 2024 stronger with impressive gains. A lackluster trading persisted ...

As previously reported, Guggenheim downgraded Acadia Pharmaceuticals (ACAD) to Neutral from Buy with a price target of $20, down from $23. The ...

ACADIA Pharmaceuticals Inc (ACAD) stock saw a modest uptick, ending the day at $18.35 which represents a slight increase of $1.66 or 9.95% from the prior close of $16.69. The stock opened at $18.24 ...

Guggenheim analyst Yatin Suneja downgraded Acadia Pharmaceuticals (ACAD) to Neutral from Buy with a $20 price target Don't Miss Our New Year's ...